Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven J Cohen

Showing results (41-50 of 102) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2012
Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancerPatricia A Tang, Steven J Cohen, Christian Kollmannsberger, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 6, 2007
Development and implementation of a medical oncology quality improvement tool for a regional community oncology network: the Fox Chase Cancer Center Partners initiativeMargaret A O'Grady, Elena Gitelson, Ramona F Swaby, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2016
A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium studySteven J Cohen, Bert H O'Neil, Jordan Berlin, et al.
Journal of Gastrointestinal Cancer|July 11, 2012
The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinomaTracy Klayton, Tianyu Li, Jian Q Yu, et al.
Pancreas|July 31, 2008
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinomaSteven J Cohen, R Katherine Alpaugh, Irma Palazzo, et al.
Annals of Surgical Oncology|September 28, 2011
Significance of pathologic response to preoperative therapy in pancreatic cancerYun Shin Chun, Harry S Cooper, Steven J Cohen, et al.
British Journal of Cancer|August 3, 2016
Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot StudyNamrata Vijayvergia, Patrick M Boland, Elizabeth Handorf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancerSteven J Cohen, Cynthia G Leichman, Gwen Yeslow, et al.
Journal of Gastrointestinal Cancer|February 2, 2012
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research studyEfrat Dotan, Neal J Meropol, Barbara Burtness, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2009
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancerSteven J Cohen, Mark M Zalupski, Manuel R Modiano, et al.
Pageof 11

Showing results (41-50 of 102) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2012
Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancerPatricia A Tang, Steven J Cohen, Christian Kollmannsberger, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 6, 2007
Development and implementation of a medical oncology quality improvement tool for a regional community oncology network: the Fox Chase Cancer Center Partners initiativeMargaret A O'Grady, Elena Gitelson, Ramona F Swaby, et al.
Cancer Chemotherapy and Pharmacology|February 18, 2016
A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium studySteven J Cohen, Bert H O'Neil, Jordan Berlin, et al.
Journal of Gastrointestinal Cancer|July 11, 2012
The role of qualitative and quantitative analysis of F18-FDG positron emission tomography in predicting pathologic response following chemoradiotherapy in patients with esophageal carcinomaTracy Klayton, Tianyu Li, Jian Q Yu, et al.
Pancreas|July 31, 2008
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinomaSteven J Cohen, R Katherine Alpaugh, Irma Palazzo, et al.
Annals of Surgical Oncology|September 28, 2011
Significance of pathologic response to preoperative therapy in pancreatic cancerYun Shin Chun, Harry S Cooper, Steven J Cohen, et al.
British Journal of Cancer|August 3, 2016
Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot StudyNamrata Vijayvergia, Patrick M Boland, Elizabeth Handorf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancerSteven J Cohen, Cynthia G Leichman, Gwen Yeslow, et al.
Journal of Gastrointestinal Cancer|February 2, 2012
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research studyEfrat Dotan, Neal J Meropol, Barbara Burtness, et al.
Cancer Chemotherapy and Pharmacology|October 27, 2009
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancerSteven J Cohen, Mark M Zalupski, Manuel R Modiano, et al.
Pageof 11